A Korean expert has given a positive evaluation to the phase 3 clinical trial results of VEGFR2 Tigit Tyrosine Kinase Inhibitor (TKI), “rivoceranib,” which proved effective in the first-line treatment of liver cancer combined with the anti-PD-1 immuno-cancer drug, "camrelizumab."
Please refer to the following website for further details:
http://www.koreabiomed.com/news/articleView.html?idxno=14572